You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Skip to content

KNOW YOUR RISK FOR GLAUCOMA

Frequently Asked Questions

High eye pressure is a condition that may cause damage to the optic nerve. If there is no damage to the optic nerve, you do not have glaucoma, but you may be at risk of developing glaucoma in the future.1 Eye drops, such as XELPROS™, reduce high eye pressure in patients with open-angle glaucoma or ocular hypertension.2

Patients with high eye pressure are at greater risk of developing glaucoma or further progression of the disease. Some people can get glaucoma without having high eye pressure. Your risk for developing this disease is as unique as you are. High eye pressure in 1 person may be normal in another. Your healthcare provider will find the level of eye pressure that is normal for you.1

Made of more than 1 million nerve fibers, the optic nerve is the cord that connects your eyes to your brain. In the eye, fluid leaves the surface all the time as with a drain. In open-angle glaucoma, fluid in the corner, or angle, of your eyes is slow to drain, which raises your eye pressure. High eye pressure damages the optic nerve, leading to vision loss.1

XELPROS can help lower the high pressure in your eye, which can cause further damage to the optic nerve, if not reduced.2

INDICATIONS AND USAGE

XELPROS (latanoprost ophthalmic emulsion) 0.005% is a prescription medication for the treatment of high eye pressure (known as intraocular pressure, or IOP) in people with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

XELPROS is not recommended in patients with a known hypersensitivity to latanoprost, or any other ingredients in this product.

Some patients may experience darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes while taking XELPROS. This darkening effect may increase as long as XELPROS is administered, and eye color changes are likely to be permanent. The increased growth and thickening of the eyelashes are reversible when XELPROS is discontinued.

Patients should avoid touching the tip of the dispensing container to the eye or surrounding areas during administration because this could cause the tip to become contaminated by common bacteria known to cause eye infection. Serious damage to the eye and subsequent loss of vision may result from using a contaminated product.

Contact lenses should be removed prior to the administration of XELPROS. Contact lenses can be reinserted 15 minutes following administration.

If more than one topical eye medication is used, the drugs should be administered at least 5 minutes apart.

The most common side effects of XELPROS may include eye pain/stinging, eye redness, eye discharge, growth of eyelashes, and eyelash thickening.

Patients who have eye surgery, develop an eye condition, or any other reaction while taking XELPROS should consult their eye doctor concerning the continued use of this product.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Please see the Full Prescribing Information.

References: 1. National Eye Institute. Information for healthy vision. https://nei.nih.gov/glaucoma. Accessed April 23, 2019. 2. XELPROS™ [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc;